DDInter1592 DDInter1492
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Rifapentine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) AGL
AGL {u} (Gene) is regulated by {v} (Gene) KDR
KDR {u} (Gene) is bound by {v} (Compound) Ponatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Rifapentine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Ponatinib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifapentine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifapentine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound)
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifapentine (Compound) upregulates AGL (Gene) and AGL (Gene) is regulated by KDR (Gene) and KDR (Gene) is bound by Ponatinib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib